Matthew Neil
– New practices will support companies across all of their healthcare corporate affairs requirements and help them communicate with investors, industry, media, and political stakeholders.
– 5654 Health & Life Sciences works with companies to communicate and attract long-term sustainable growth capital
LONDON, May 7, 2024 (GLOBE NEWSWIRE) — 5654 & Company, a leading independent corporate affairs consultancy with a proven track record of delivering industry-leading work and results, today announced the acquisition of 5654 Health & Life Sciences. We announced the launch of a new practice method. We support companies across all of their healthcare business requirements. This new practice was established to help health and life sciences companies grow and communicate with key investors, industry, media and political stakeholders. Matthew Neal, formerly of ICR Consilium, joins the firm as partner and director of 5654 Health & Life Sciences to lead the practice's growth.
Michelle Donnellan MP, Secretary of State for Science, Innovation and Technology, commented: “As our experience with COVID-19 has shown, the UK life sciences sector is at the forefront of global medical innovation, leading the way in saving lives and improving our health. The government is committed to supporting the sector with hundreds of millions of pounds to drive innovation and grow the economy. We welcome the launch of this new service by 5654 & Company as it is critical to the creation of skilled jobs.”
5654 & Company works with clients to create insight-driven communications campaigns designed to support commercial, investor, and political objectives. 5654 Health & Life Sciences leverages the expertise of our entire in-house team to deliver a wide range of services including strategic healthcare communications, capital markets communications and investor relations, M&A and activism advice, crisis communications, public relations, and development communications. Deliver features and services instantly. and digital marketing communications. 5654 & Company's single structure allows us to create bespoke integrated teams for each client, matching skills and talent across the company to their needs.
Ben Thornton, founding partner of 5654 & Company, said: “The innovation and talent that the UK life sciences sector produces is enviable on a global scale. However, the current investment environment for growth companies is hindering the growth of the sector. This is why we are implementing new practices. That's why we launched Health & Life Sciences. Our aim is to help the UK become a health and life sciences superpower, with a vibrant life sciences that fosters innovation and jobs and drives the UK economy forward. We are excited to have Matthew as a leader in this area and share his passion for success in this area, as he brings new and differentiated services to the market. I am confident that he will join a team with the expertise to rapidly grow our company into a leader in healthcare enterprise practice.”
5654 Health & Life Sciences is a group of companies and organizations at various stages of maturity that are driving innovation and developing treatments, technologies, and ways of working that lead to better outcomes for patients, investors, health systems, and payers. We are collaborating with This includes biotech, pharmaceutical, medical technology, health tech, and diagnostic companies. Hospitals, healthcare providers, healthcare services, and consumer pharmaceutical companies. Real estate and research lab developer. global technology. investors, governments, industry and public bodies. The practice works with companies in communications throughout the investment and growth cycle, including venture financing, institutional and government investment, strategic partnerships, licensing, leadership and board development, IPOs, and M&A.
Matthew Neal, partner and principal at 5654 Health & Life Sciences, said: “The UK life sciences sector is a world leader in innovation and R&D, but there is a funding gap for companies as they mature from venture rounds to IPOs and exits. It's time to take action and challenge the status quo by removing barriers and helping change the way we approach funding. I'm excited to join Ben and the team to launch the 5654 Health & Life Sciences offer. This new practice supports communications with investors, industry, and political stakeholders who support company growth and provide access to sustainable growth capital and long-term liquidity. To do.”
Note to editor
5654 & Company was founded in 2020 with the purpose of helping companies take action to gain reputation and support. 5654 is an independent mid-market consulting firm. Our experienced consulting team works with clients to communicate with evidence and emotion to shape the voice of the entire audience. 5654 works with some of the world's most famous companies and brands.
5654 & Company is a proud supporter of the Biotechnology Industry Association. Click this link for more information. He is also a member of the PRCA, is a signatory to the Public Affairs Code and is a statutory consultant listed on his Lobbyist Register.
For more information about 5654 & Company, please visit www.5654.co.uk.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/087449d3-d816-411f-bd70-4fa5adebc6a5.
CONTACT: To learn more about the 5654 Health & Life Sciences practice or how it could support your growth and communications objectives, please contact healthandlifesciences@5654.co.uk.
